BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36857149)

  • 1. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
    Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
    Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
    Foulkes SJ; Howden EJ; Haykowsky MJ; Antill Y; Salim A; Nightingale SS; Loi S; Claus P; Janssens K; Mitchell AM; Wright L; Costello BT; Lindqvist A; Burnham L; Wallace I; Daly RM; Fraser SF; La Gerche A
    Circulation; 2023 Feb; 147(7):532-545. PubMed ID: 36342348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    Kirkham AA; Paterson DI; Prado CM; Mackey JR; Courneya KS; Pituskin E; Thompson RB
    BMC Cancer; 2018 Sep; 18(1):864. PubMed ID: 30176834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy.
    Foulkes SJ; Howden EJ; Bigaran A; Janssens K; Antill Y; Loi S; Claus P; Haykowsky MJ; Daly RM; Fraser SF; LA Gerche A
    Med Sci Sports Exerc; 2019 Aug; 51(8):1573-1581. PubMed ID: 30829962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 8. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
    Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
    Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
    Jacquinot Q; Meneveau N; Falcoz A; Bouhaddi M; Roux P; Degano B; Chatot M; Curtit E; Mansi L; Paillard MJ; Bazan F; Chaigneau L; Dobi E; Meynard G; Vernerey D; Pivot X; Mougin F
    Front Cardiovasc Med; 2022; 9():1000846. PubMed ID: 36211552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol.
    Foulkes SJ; Howden EJ; Antill Y; Loi S; Salim A; Haykowsky MJ; Daly RM; Fraser SF; La Gerche A
    BMC Cancer; 2020 Jul; 20(1):655. PubMed ID: 32664946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
    Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
    Jacobse JN; Steggink LC; Sonke GS; Schaapveld M; Hummel YM; Steenbruggen TG; Lefrandt JD; Nuver J; Crijns APG; Aleman BMP; van der Meer P; Gietema JA; van Leeuwen FE
    Eur J Heart Fail; 2020 Feb; 22(2):338-346. PubMed ID: 31696625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supervised exercise training in patients with cancer during anthracycline-based chemotherapy to mitigate cardiotoxicity: a randomized-controlled-trial.
    Schneider C; Ryffel C; Stütz L; Rabaglio M; Suter TM; Campbell KL; Eser P; Wilhelm M
    Front Cardiovasc Med; 2023; 10():1283153. PubMed ID: 38111886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
    Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
    ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
    Hamidian M; Foroughinia F; Haghighat S; Attar A; Haem E
    J Oncol Pharm Pract; 2023 Sep; 29(6):1306-1316. PubMed ID: 35975564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
    Barac A; Lynce F; Smith KL; Mete M; Shara NM; Asch FM; Nardacci MP; Wray L; Herbolsheimer P; Nunes RA; Swain SM; Warren R; Peshkin BN; Isaacs C
    Breast Cancer Res Treat; 2016 Jan; 155(2):285-93. PubMed ID: 26749359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise Training Benefits Health-Related Quality of Life and Functional Capacity during Breast Cancer Chemotherapy: A Randomized Controlled Trial.
    Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Oliveira J; Capela A; Amarelo A; Leão I; Marques C; Viamonte S; Alves A; Esteves D
    Med Sci Sports Exerc; 2024 Apr; 56(4):600-611. PubMed ID: 38051110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
    Liu Z; Liu M; Zhong X; Qin Y; Liang T; Luo T; Yan X; Tang Z; Wang X; Liang S; Li Q; Ruan X; He W; Huang H
    Cancer Med; 2023 Jun; 12(12):13374-13387. PubMed ID: 37183826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.